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Thepotentialofbiologicmarkerstoprovidemoretimelyandpreciseriskassessmentsforenvironmentalcarcinogens
isviewedagainst thecurrentstate-of-the-artinbiologicalmonitoring/molecularepidemiolo.Biologicmarkerssuchas
carinogen-DNAadductsandoncogeneactivationarecurrentlyconsideredvalidqualitativeindicatorsofpotentialrisk,
butformostchemicalexposuresresearch isneededtoestablih theirvalidity asquantitative dtorsofcancerrisk.
Biologic markers have, however, already providedvaluableinsights intothe uagnitude ofinterindividual variation in
response tocarcinogenic exposures, withmajorimplications forriskassessnent.
Introduction
Cancerprevention remains anunfulfilledgoalbecauseofthe
limited tools available to make timely and meaningful risk
estimates for environmental carcinogens. Traditionally, these
estimates havebeenbased ondose-responsedataderived from
controlled experiments ingenetically homogeneous laboratory
animals. Generally, responseattherelevantlowlevelofexposure
isextrapolatedfromresultsobserved atdoses severalordersof
magnitude higher. In rare cases, dose-response data from
epidemiologic studies (usually fromtheoccupational inbothin-
stances, setting) areused. However, thedoseisthe amountofcar-
cinogenadministered ortheexternal exposurerather thanthe ac-
tual targetdose, andthe responseisthetumoryield. Inaddition,
eventhe mostconservativeriskextrapolation modelsmakethe
simplifying assumption that the human population is
homogeneous in itsbiologic response to carcinogens.
Biologicmarkershavethepotential toimproveriskassessment
in anumberofspecific areas. First, markers canprovide quan-
titative estimates ofthe biologically effective dose ofthe car-
cinogen to the target tissue. Calibration ofmolecular dose in
humans tothatinlaboratoryanimals forwhomtumorevidence
isknownshouldgreatlyenhanceextrapolationofrisksbetween
species. Second, markers of preclinical biologic response
(establishedtobepredictiveofcancerrisk) canprovide anearlier
occurring, more sensitive outcome than tumorincidence. Thus,
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markerscanallowepidemiology toescapethetyrannyofcancer
latencytobecomeamoretimelycontributortoriskassessment
andcancerprevention. Third, markerscanprovideinformation
on interindividual variation in response to a carcinogenic ex-
posure,therebyfillingamajorvoidinriskassessment. Fourth,
biologicmarkerscanhelpidentifythemechanismsbywhichcar-
cinogensexerttheireffect, thusenablingmoreeffectivepreven-
tion strategies.
Thefieldofbiologicmarkersisstill, however, atanearlystage
ofdevelopment. Animpressivenumberofstudieshave related
increasesinbiologicmarkerssuchascarcinogen-DNAadducts,
geneticalterations, andoncogeneactivationtospecificoccupa-
tionalorlifestyleexposures,demonstratingtheabilityofmarkers
to flag carcinogenic hazards (qualitative risks). Much less
researchefforthasbeenaimedatevaluatingdose-responserela-
tionshipsbetweenexposureandmoleculardoseoreffect. Inmost
cases,peripheralbloodcellshavebeenassayedasasurrogatefor
target tissue. In addition, much work remains to establish the
value of biologic markers as quantitative predictors of car-
cinogenicrisk. Wecanpointtoonlyonecaseofawell-developed
quantitative risk assessment based upon biomonitoring data
(1-3). Although considerable progress has been made using
biologic markers that reflect a genotoxic end point, there is a
dearthofmethodsforbiomonitoring individualswithexposure
tocarcinogens(suchasdioxinandthechlorinatedorganics)that
do notinteractefficiently withthegeneticmaterial.
Thepurposeofthispaperistwofold. First, wewillhighlight
recent progress in the validation ofbiologic markers to better
assess their potential in risk assessment. The common
denominator in our review will be carcinogen-DNA or car-
cinogenproteinadducts(asameasureofbiologically effectivePERERA ETAL.
Table 1. Biologcl markers insmokers and nonsmokers (14).
Mean (SE)
Marker Smokers Nonsmokers
4-ARP-Hb, pg/g 154.5 (11.3)* 32.2 (2.9)
n 19 18
SCE, average/metaphase 10.8 (0.603)t 8.1(0.47)
n 11 10
Cotinine, ng/mL 419.2 (47.4)* 0.3 (0.032)
n 10 10
*p = 0.0001.
tp = 0.002.
dose) inconjunction with acomplementary markerofbiologic
effect (oncogene activation). Second, we will review available
informationregardingthemagnitudeofinterindividualvariation
inmolecular orcellularbiologic responsetocarcinogens. This
information will serve as the basis for estimating the degree
to which failure to incorporate interindividual variation
intoquantitativeriskassessment mayleadtounderestimationof
risk.
Recent Research on Macromolecular
Adducts and Oncogene Activation
There is a strong biologic rationale for selecting macro-
molecular adducts and oncogene activation. Adducts result
from covalent interaction of electrophilic carcinogens with
DNA. Ifunrepaired, DNA adducts can lead to gene mutation
and initiation ofcancer. Protein adducts can serve as an easily
obtainedsurrogateforthoseformedwithDNA. Variousmethods
are available to measure adducts, including immunoassays,
spectrometry, andpostlabeling (4). Carcinogen-DNA binding
is considered to be a necessary but not sufficient event in
chemical carcinogenesis (5-11).
Activated oncogeneshavebeenidentified inhumantumorsof
all types and in commonpremalignantlesions, suggesting that
oncogenes represent asufficiently early stepinthecarcinogenic
process to allow for clinical intervention. Moreover, activated
oncogenes havebeenlinkedexperimentally andinhumanstudies
to exposure to carcinogens including polycyclic aromatic
hydrocarbons (PAHs) (12). Using monoclonal antibodies and
modifiedWesternblottingtechniques, itis nowpossibletodetect
oncogeneproteinproductsintumortissueandinurine or serum
as surrogates fortargettissue(13).
Because the design of biomonitoring studies so strongly
dictates the interpretation ofdata, we will review examples of
cross-sectional, longitudinal serial sampling, case-control,
and nested case-control studies using these and related bio-
markers. The preponderance ofresearch on macromolecular
adductshasbeencross-sectionalin nature, aimedatelucidating
therelationshipbetweencarcinogen-DNA orcarcinogen-protein
adducts and estimated exposure to carcinogens such as cigar-
ette smoke, diet, industrial pollution, and combination
chemotherapy.
Cigarette smoke is a classical complex exposure that
has been the subject of much molecular analysis. For ex-
ample, in a study of22 cigarette smoking and 24nonsmoking
volunteers (Table 1), a battery of markers was evaluated
in repeat peripheral blood samples drawn several days apart
(14). Environmental histories were obtained by questionnaire.
4-Aminobiphenyl-hemoglobin (4-ABP-Hb) adducts mea-
sured by GC/MS were found to be more specific to cigar-
ette smoke than PAH-DNA adducts measured by (ELISA)
immunoassay. Unlike PAH-DNA adducts for which there
was a high and variable background, 4-ABP-Hb levels were
significantly different (p = 0.0001) in smokers and non-
smokers. A repeat blood sample (2 days later) gave compa-
rable results for 4-ABP-Hb: 139.0 (7.9) pg/g for the smokers
versus 36.2 (5.02) for the nonsmokers. The frequency of
sister chromatid exchange (SCE) was also significantly
elevated in the smokers and was positively correlated with
4-ABP-Hb. This finding suggests that aromatic amines
contribute significantly to the integrated genotoxic effect of
cigarette smoke.
Ethylene oxide (EO) is another genotoxic constituent of
cigarettesmoke. Recently, samplesfrom asubsetoftheoriginal
group were analyzed forethylene oxide-hemoglobin (EO-Hb)
adducts by the procedure of Tornqvist et al. (15). The levels
of EO-Hb (hydroxyethyl valine) adducts were significantly
higher in smokers (n = 13) than nonsmokers (n = 7) (16).
Ethyleneoxideand4-aminobiphenyl adducts werehighly cor-
related(r = 0.83)inthesmokersandnonsmokerscombinedand
inthe smokers as a group (r = 0.50, p < 0.0005).
Table2. DNAadducts inwhitebloodcellsofsmokersand no rs
Range, Meanpositive
Assay Population (n) Amole/molea % Positive pmole/moleb Reference
PAH-DNA, Smokers (22) 0.054-0.17 41 0.096 (14)
ELISA (3x)
Nonsmokers (24) 0.035-0.14 33 0.08
(4x)
PAH-DNA, Smokers (32) <0.032-0.29 9 0.192 (43)
USERIA (>9x)
Nonsmokers (49) <0.032-0.13 4 0.096
(> 4x)
DNAadducts, Smokers (4) <0.002-0.014 100 0.0065 (44) 32p (> 7x)
Nonsmokers (6) 0.004-0.01 100 0.0065
(2.5x)
'Values are umoleadduct permole DNA. ELISA, enzyme-linked immunosorbent assay;USERIA,ultrasensitive enzymaticradioimmunoassay;
32p 32P-postlabeling. Values inparentheses showthe rangeofadducts seenacross all samples, e.g., 3-fold.
bihevaluegiven isthemeanforpositive samples; i.e.,those withdetectable levels ofadducts.
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This study design has the advantage of simplicity and
feasibility. However, hadthedifferences between the two groups
(smokers and nonsmokers) been smaller, they might have been
missed because ofswamping by interindividual variability. For
example, a 32% coefficient of variation was seen in levels of
4-ABP-Hb among the smokers, all ofwhom smoked between
1 and 2 (mean, 1.4 + 0.4) packs per day.
In this study the coefficient of variation for samples
with detectable levels of PAH-DNA adducts was 38% in
the smokers compared to 40% in the nonsmokers. In Table
2, the results for PAH-DNA are compared with adduct
data by immunoassay and postlabeling on smokers and
nonsmokers from two other laboratories. Across all stu-
dies, the range in binding levels was 3-fold to greater
than 9-fold among smokers, compared to 2.5-fold to greater
than 7-fold among nonsmokers. This high and variable
background in DNA adducts has been consistently seen in
human studies, except for those involving administration of
certain drugs.
In contrast to the smoker/nonsmoker study, a cross-sectional
study of PAH-DNA in long-term employees in an iron foun-
dry in Finland showed a clear dose-response relationship bet-
ween estimated source-specific exposure to PAH and levels of
PAH-DNA adducts (p = 0.0001) (17). Thirty-five workers were
classified into three categories according to their estimated
exposure to benzo(a)pyrene (BaP) as a representative PAH:
high exposure (8-hr time-weighted average > 0.02 Ag/m3);
medium exposure (0.2-0.05 ,ug/m3); or low exposure (< 0.5
tig/m3). Controls were 10 workers with no occupational
exposure to PAHs. Here, also, significant interindividual varia-
tion was seen in addduct levels in the exposed workers. For
example, in 13 foundry workers with comparable medium ex-
posure (0.05-0.2 Ag/m3 BaP) there was a 20-fold range
of PAH-DNA adducts (0.03-0.7 pmole/mole); for the low
exposure group (n = 18), a 29-fold range ofPAH-DNA adducts
(0.01-0.28 ,Amole/mole) was observed. These results are
consistent with data for exposed workers in otheroccupational
biomonitoring studies. As shown in Table 3, the levels of
PAH-DNA adducts in coke oven and foundry workers in three
other studies showed a similar range (>3-137x) as did DNA
adducts by the postlabeling method (< 50x).
Recently, we have investigated whether levels ofPAH-DNA
adducts (as a marker ofbiologically effective dose) correlated
with activation of oncogenes (as a marker of biologic effect)
since various PAHs havebeen shown experimentally to activate
the ras oncogene (18,19). Therefore, sera from foundry workers
and controls were assayed for oncogene protein products (ras,
fes, myc, mryb, sis, B-EGF, int-i, myb, src, andmos) as previous-
ly described (20).
The method was able to determine whether the oncogene
was overexpressed but not whether it had undergone a point
mutation. A fivefold increase in protein expression was point
considered a positive result. As shown in Table 4, one in-
dividual in the medium exposure group showed elevated levels
of the ras oncogene product in one of three serum samples
tested. Repeat serum samples from two other individuals in
themediumandhigh exposure groupshad significantly elevated
levels ofthefes oncogene protein product. Samples from the
10 unexposed controls were uniformly negative. As will be
discussed, bothfes and ras serum proteins have been detected
in lung cancer patients and cigarette smokers. Since foundry
workers are also at elevated risk of lung cancer (21), these
results suggest that oncogene activation may prove to be a useful
early marker for respiratory cancer related to PAH exposure.
Obviously, this clue must be followed up by further studies.
As with all cross-sectional studies, which provide a snap-
shot at aparticularpoint in time, this research cannot establish
temporal or causal relationships between exposure, adduct
formation, and oncogene activation. For this reason,
longitudinal studies in individuals whose exposure changes
significantly over time are preferable in terms ofestablishing
the relationship between exposure and biologic markers.
Recently, we carried out a pilot serial sampling study of
"'smokenders," obtaining repeat blood samples from 21 active
smokers upon enrollment into the smoking cessation program
and then 21 days and 3 to 6 months after enrollment (22).
Roughly half of the individuals quit smoking entirely within
3 weeks (stoppers) and the other halfeither reduced smoking
or continued to smoke at the same level (nonstoppers). SCEs
were significantly decreased in the stoppers (but not the
nonstoppers) at least 3 to 6 months after quitting, while levels
of4-ABP-Hb and cotinine fell sharply within 21 days. However,
PAH-DNA adducts were not significantly affected by smok-
ing cessation,
Table 3. PAH-DNA in white blood cells of workers.'
Range, Mean positive
Assay Population (n) iAmole/moleb % Positive ,tmole/molec Reference
PAH-DNA, Coke oven <0.032-0.13 35 0.064 (45)
USERIA (20) (> 4x) (0.022)
PAH-DNA, Coke oven <0.032-10.9 66 2.27 (40)
ELISA (27) (> 3.4x) (1.51)
PAH-DNA, Coke oven <0.032-4.38 34 0.51 (4!)
USERIA (38) (>137x) (0.18)
PAH-DNA, Foundry <0.01-0.90 86 0.20 (11)
ELISA (35) (> 90x) (0.17)
DNA adducts, Foundry' <0.002-0.1 100 0.018 (46)
32p (25) (> SOx)
aValues are jAmole adduct per mole DNA. ELISA, enzyme-linked immunosorbert assay; USERIA, ultrasensitive enzymatic radioimmunoassay.
'Values in parentheses show the range of adducts seen across all samples, e.g., 4-fold.
cThe value given is the mean for positive samples; i.e., those with deductible levels of adducts. Values in parentheses are means for all samples assayed.
dMedium and high exposed.
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Table 4. PAH-DNAadducts and serum oncogene protein expression in foundry workers and unexposed controls (12).
Ambient PAH-DNA adduct levels, Serum oncogeneproteins'
exposure, Subject fmole/4g_ fes ras
,sg BaP/m3 number Cigarettes/day Post vacation Work 1 Work2 Post vacation Work 1 Work2 Post vacation Work1 Work2
>0.2 (high 1 0 0.11 0.8 NA
exposure) 2 20 0.13 2.0 NA + +
3 0 NAb 2.8 NA - - - -
0.05-0.2 4 15 0.13 0.36 NA - - - -
(medium 5 20-25 NA 0.32 0.32 - - - - +
exposure) 6 15 NA 0.8 0.5 - -
7 0 0.48 1.28 NA + + - -
8 20 NDb 0.4 NA - - - -
0.05 (low 9 20 ND 0.38
exposure) 10 ND 1.52
11 ND 0.32
12 0.08 1.20
0 (unexposed 9 15 0.08
controls) 10 10 ND
11 0 0.14 - -
12 0 ND - -
13 0 ND - -
14 0 0.3 - -
15 0 ND - -
16 10 ND - -
17 15 0.1 - -
18 0 0.1 - -
aPost vacation samples weredrawnaftera 1 month vacation; work 1 samplesforworkers (butnot forcontrols) weredrawn6weeksafterreturningtowork; work
2 samples were drawn more than 2 months after returning to work.
bNA, not available; ND, nondetectable.
possibly becauseoftheirlackofspecificity forcigarette smoke
constituents and/or the short follow-up period.
Based on these results, we are beginning a more definitive
studyofsmokenders whowillbefollowed for2 yearsafterquit-
ting to evaluate persistence ofDNA adducts, hemoglobin ad-
ducts, and oncogene protein products. We will also be
evaluating several potential genetic/metabolic markers of
susceptibility including arylhydrocarbon hydroxylase (AHH)
activity and glutathione-S-transferase activity. This approach
will allow a detailed evaluation ofthe persistence ofbiologic
markers in human peripheral blood cells.
Another natural experiment was provided by theplant-wide
annual vacationtakenbytheFinnishfoundry workersduringthe
monthofJuly. Asshown inTable4, whitebloodcellDNAfrom
individuals was assayed for PAH-DNA adducts after the
workers returned from their 4-week vacation (sample 1) and
then 6 weeks following their return to work (sample 2). The
levelsofadducts weresignificantly higher (p = 0.002, Wilcox-
onsignranktest) insample2, showing aclearbiologiceffectof
exposure.
Another longitudinal, serial sampling study has evaluated
biologic markers inpatientstreated withcisplatinum (cisDDP)-
based chemotherapy (23) (Table5). Peripheral blood samples
werecollectedjustpriortoandfollowingthefirst, second, and
lastcycles ofchemotherapy. In subjects with abaseline and at
leasttwopost-treatment samples, levelsofSCE, plasmaprotein
binding, andhemoglobinbinding measuredby atomicabsorp-
tion spectrometry (AAS) weresignificantly increasedfollowing
treatment (p<0.01). This finding was consistent with prior
studiesofDNAandprteinadductsand SCE incisDDP-treated
patients (24-26).
Since cisDDP-based chemotherapy is standardized to body
Table 5. Levelsofbiomarkers in cisplatinum-treated patientsby timepointofsamplecolection (23).'
Baselineb Postcycle Ic Precycle 2b Postcycle2d Post final cycle*
(0) (99.23 ± 13.3.24) (105.45 ±28.41) (197.00 ± 35.82) (351.9 ± 60)
SCE 10.8 ± 3.01 17.39 ± 6.52* 17.45 ± 5.03* - -
(12) (12) (12)
Plasmaproteinbg, Ag/g 0.47 ± 1.07 27.5 ± 9.34* 2.37 ± 3.34 33.37 11.07* 33.49 ± 9.77*
(10) (10) (2) (10) (10)
Hemoglobin bg, Ag/g 0.01 ± 0.04 2.08 ± 1.04* 2.97 ± 1.25* 2.89 ± 1.04
(I11) (1) (1) (4)
aValues in parentheses aren; values inbrackets arethe averagecumulative doseofcisplatinum(mg/M2) received priortothatsamplecollection. Subjects with
baseline and at least two post-treatment samples (SCE orprotein bg).
bSamples drawn within 24 hrprior to treatment.
CSCE sample drawn 2 weeks aftertreatment; protein sampledrawn 12-24 hrpost-treatment.
dSCE and/orprotein sampledrawn 12-24hrpost-treatment.
*p < 0.01, Wilcoxon and t-tests.
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TAble6. Adductsincisplatinum-treated patients.
Assaya Tissue n Range Reference
DNA adducts, ELISA Peripheral blood lymphocytes 45 0- > 0.066Amole/mole (24)
DNA adducts, LC, ELISA Peripheral blood lymphocytes 6 0.2-1.4 umole/mole (25)
DNA adducts, immunocytochemistry Buccal mucosa 9 0->150 nucleardensity (48)
Protein adducts, AAS Hemoglobin 32 0.2-4 ng/mg (20x)b (26)
Protein adducts, AAS Hemoglobin 18 0-3.49 ng/mg (23)
aELISA enzyme-linked immunoassay; LC, liquid chromatograph; AAS, atomic absorption spectrophotometry.
bTwentyfold variability or range ofadducts.
weight or surface area of patients, it provides a good model
for examining interindividual variability. cisDDP reacts
directly with DNA, unlike the aromatic hydrocarbons which
require metabolic activation; therefore, interindividual dif-
ferences among patients would be due to uptake and retention
ofthe drug and repair ofadducts. Table 6 provides the results
ofour recent study in the context ofother reports on cisDDP-
treated patients. For 18 subjects given one cycle of chemo-
therapy, the mean level ofhemoglobin adducts was 1.90 ± 0.99
(coefficient of variation = 52%). The range of hemoglobin
adducts in samples with detectable levels was 0.35 to 3.49
tg/g or about 10-fold. One individual showed no measurable
adduct formation after treatment. Among all four studies in
Table 6, therangeofDNAadduct formation was atleast 10- to
20-fold.
Wehaverecentlybegunafollow-upstudythatwillassessafull
batteryofmarkers: cisDDP-DNAandcisDDPhemoglobinad-
ducts, SCE and micronuclei, chromosomal aberrations, gene
mutation(HPRTandGPA)andoncogeneactivationinperipheral
bloodcells and/or semen.
To summarize, theadvantageoflongitudinal serial sampling
studies such as those described is that the problem ofinterin-
dividualvariationismitigatedbyhavingeachindividualserveas
hisorherowncontrol. However, suchresearchopportnitiesare
rare, and, although they address the temporal relationship be-
tweenexposureandbiomarkers, theyleaveunansweredtheques-
tion ofwhether biomarkers are related to cancer risk.
Thefirststepinunderstanding theroleofvariousbiomarkers
asriskfactorsforcancerhasbeentakeninseveralmodifiedcase-
control studies. Thesehaveapracticaladvantageoverprospec-
tive studies interms offeasibility andcanprovidecircumstan-
tialevidenceofanassociation betweenbiomarkers andcancer
risk. However, as with cross-sectional studies, case-control
studiescannotestablishthetemporalsequenceforadductforma-
tion, gene mutation, oncogene activation, and cancer. The
retrospectiveapproachalsosuffersbecausetherelevantexposure
periodformostcancerinductionisyearstodecadesinthepast,
andbiologicmarkersformedatthatcriticaltimearelikelytobe
lostordilutedout. Only insituations whereexposurehasbeen
continuous andunchangedandwheremetabolicprocesseshave
notalteredovertime, canbiologicalmeasurementstakeninthe
present be informative.
Wehaverecently evaluated 81 caseswithprimarycarcinoma
ofthelungand67controlsforlevelsofPAH-DNAadductsand
SCEs in order to examine whether, when lifetime exposure to
PAHs andother mutagens/carcinogens was comparable, cases
had higher levels ofbiomarkers than control (23). This would
suggestthattheabilitytoefficientlyactivateandbindcarcinogens
mayhavebeenariskfactorintheirdisease. SCEsinlymphocytes
did not differ between cases and controls. As in the
smokers/nonsmokers study, PAH-DNAadductsinwhiteblood
cellDNAwerenotspecifictocigarettesmokingbutapparently
reflectedthenumerousbackgroundsourcesofPAHsuchasdiet
andambientair. Amongcurrentsmokers, lungcancercaseshad
significantly higher levels of PAH-DNA adducts (p = 0.01,
Wilcoxon ranksum test). This case-control difference was en-
tirelycontributedbybloodsamplescollectedduringthemonths
ofJulythroughOctober. This seasonaleffectisconsistentwith
the observation ofseasonal variation AHH activity in human
lympocytes (27). Genetically regulatedmetabolismofPAHs by
theAHHmicrosomal enzymesystemhasbeenlinked (in some
but notall studiesundertaken) to lung cancer risk(28,29).
As inthefoundry workersstudy, Westernblottingtechniques
wereusedtoscreenseraof18lungcancercasesandcontrolsfor
peptidesequencesofninedifferentproteinsincludingras,fesand
myc. As shown in Table 7, 18 cases, all current or former
smokers, werepositiveforatleastoneoncogeneprotein, incon-
trastto2ofthe20healthycontrols (bothcurrentsmokers). In 15
of these cases, all but one of which were nonsquamous cell
cancers, rasgeneproteinproductswereidentified. Elevenof18
caseshadactivatedfescomparedto0ofthecontrols. Allofthe
lung cancer patients were former or current smokers. These
resultsareconsistentwithpriorstudiesinthatPAHsareknown
toactivatetherasgene, andahighprevalanceofactivatedrMshas
been seen in nonsmall cell carcinomas and in tumors from
cigarette smokers. Highlevelsoffesexpressionhavealsobeen
detected inhumanlung tumors (12).
PAH-DNAadductsandSCEsweremeasuredinwhiteblood
cellDNAfromthese 18patients. Threeofthe 18individualshad
detectablelevelsofPAH-DNAadductsinwhitebloodcellDNA.
All3werepositiveforthe usoncoprotein; however, 11 oftheras-
positive cases did not have detectable levels ofadducts. Thus,
therewasnoapparentcorrelationbetweenadductsandoncogene
activation, possibly because of the small number of subjects
studied.
Asnotedabove, case-control studieshavetheseriouslimita-
tionthatifexposureorpharmacokineticprocesseshavealtered
between the time of cancer induction and diagnosis, current
levelsofmacromolecularadductlevelsmaybearlittlerelation-
shiptocancerrisk. Thus,thenestedcase-control istheoptimal
designforevaluatingtherelationshipbetweenbiologicmarkers
and cancer risk, provided thatthe marker is stable in samples
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Table 7. DNAadducts and serumoncogene protein in lungcancer patents (12).
Smoking
history, Thmor Lymphocyte Oncogene
Patient Age Sex pack-years type adducts (fmole/pg) ras fes myb int sis myc mos src EGF
1 75 F S(NA) A - ++ - + +
2 71 F S(90) A(S) - ++ ++
3 67 F S(31) A - ++ -
4 42 M S(20) L - ++ -
5 67 F S(40) A - ++ -
6 82 M S(55) A +(0.45) ++ -
7 49 M S(63) S - ++ -
8 65 M S(40) L +(0.16) ++ ++ +
9 68 F S(62) A - ++ ++ +
10 62 M S(61) S - - ++ -
11 69 F S(40) A - - ++ -
12 73 F S(84) S - -
13 67 F S(105) A - ++ ++
14 67 F S(13) L - ++ ++
15 60 F S(20) L - ++
16 63 M S(84) A - ++ ++
17 69 M S(50) A +(0.13) ++ ++ -
18 62 M S(30) A - ++ ++ -
Controls
19 58 M NS
29 25 M NS
21 30 M ES
22 31 M CS + (All others negative)
23 52 M ES +
24 39 M CS -
25 29 M NS -
26 34 M CS -
27 26 M NS -
28 35 M CS -
29 35 M NS -
30 52 M CS -
31 36 M NS -
32 56 M NS -
33 56 M NS -
34 32 M NS -
35 48 M CS -
36 44 M NS -
'(++) stongly positive; (+) positive; (-) negative; NA, notavailable; NS, nonsmoker; ES, exsmoker; CS, current smoker; S, smoker; A, adeno; AS, adeno-
squamous; L = large cell; S = squamous.
collected at theoutset ofaprospective study. In this approach,
thecohortis followed, andwhencancercasesappearamongthe
cohort, their stored biological samples are analyzed and com-
pared with those from one or more matched controls. The
relative risk (i.e., the measure ofassociation between the in-
cidence ratesofcancerandthebiomarkersbeingevaluated) can
then be calculated. Examples include a recent study ofserum
retinol andretinol-binding protein andlung cancer (30) andan
ongoing studyofhepatitisBchroniccarriersinvolving retrospec-
tivemeasurementofaflatoxinB1 adductsonalbuminandother
markersonceincidenthepatocellularcarcinomacasesareiden-
tified (31).
Adducts in Quantitative Risk
Assessment and Mechanistic Studies
Biological dosimetry data in humans and experimental
animalshavebeenusedtoalimitedextenttopredicthumanrisk.
Asmentioned, thebest-developedexampleisthatofEtO. Briefly,
this was calculated as follows. The tissue dose (theactual con-
centration ofthereactiveelectrophile withinthetissue) ofEtO
was assumed to be directly proportional to the extent ofboth
DNAandproteinbindinginhumans, ashadbeendemonstrated
inmiceexposedtoEtO. Thein viotissuedose(mole/hr)ofEtO
that produced the same mutagenic response in experimental
systemsas 1 radoflow-LETradiationinthelowdose-response
region was calculated and termed the "rad equivalent."
Measurements of EtO-hemoglobin binding in sterilizer plant
workers were then used to estimate their tissue dose ofEtO in
termsofradequivalents. Thisradequivalentmeasurealloweda
calculation of the excess risk of leukemia in the workers
(1,32-34). Theresultantpredictionofincreasedriskofcancerin
this cohort was subsequently borne out by epidemiological
studies (3).
AlthoughtheresultswithEtOaregenerallyencouraging, this
may be a somewhat special case because EtO is a stable elec-
trophile that distributes evenly between tissues, in contrast to
substances such as vinyl chloride and dimethylnitrosamine,
which require metabolism and thus produce less stable in-
termediates(34). Atpresent, werarelyhavecomparativedataon
adductsinhumansandlaboratoryanimalswithchronicexposure.
While this situation should improve rapidly for individual
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substances, humanexposuresfrequently involvecomplexmix-
tures that are rarely tested in laboratory animals. In addition,
humanstudiesaregenerallycarriedoutinworkerpopulations,
smokers, chemotherapy patients, oraccidental situationswhere
exposures arefarhigherthanthoseencountered bythegeneral
population. Thus, riskassessmentwill stillnecessitatelow-dose
extrapolation with its underlying assumptions.
Anelegantjuxtapositionofresultsfromaconventional case-
control study ofbladdercancer and frombiomonitoring ofin-
dividualswhowererepresentativeofthesameresourcepopula-
tionhasprovided additional circumstantial evidence thatadduct
formation iscausally relatedtocancerrisk. Thedatahavealso
provided insights intothemechanismsofbladdercancercausa-
tion. In the case-control study, the risk of bladder cancer in
T.urin, Italy, was2.5timeshigheramongsmokersofblacktobac-
co than among smokers ofblond tobacco (35).
A subsequent study of volunteers from Turin showed cor-
respondinglyhigherlevelsof4-ABP-Hbadducts inthebloodof
blacktobacco smokers compared to smokers ofblondtobacco
(36). Thedifferences inadductlevelswereapproximatelypro-
portional totherelativeriskofeachgroup. Urinarymutagenicity
was also twice as high in black tobacco smokers as in blond
tobacco smokers (37). Thesefindingswerenotsurprising since
aromatic amines, including 4-ABP, are more concentrated in
blackthanblondtobacco smoke. Giventhedifferentcomposi-
tionofblackandblondtobaccosmoke, itispossiblethatthetwo
types of tobacco affect different stages in the multistage car-
cinogenic process. Indeed, in smokers ofblacktobacco, there
wasagradientofriskwithearlyexposure; andsmokerswhohad
quitnevershowedadroptobaselinelevelsofbladdercancerrisk.
This suggests both an early and late effect of black tobacco
smoke, incontrasttoblondtobaccosmokewhichappearstocon-
tainlate-stagecarcinogens(asevidencedbythedramaticdropin
risk forblond tobacco smokers following smoking cessation).
Heretheepidemiologic databearinguponmechanismandstage
of carcinogenic action were supported by a relevant biologic
marker, 4-ABP-Hb adducts.
Need to Accountfor Interindividual
Variation in RiskAssessment
Theobserved variation inmacromolecular binding between
individuals withcomparableenvironmental orclinicalexposure
to carcinogens is consistent with data on interindividual dif-
ferences in carcinogen activation, detoxification, and DNA
repair (38,39). Although not well characterized, variation in
cellularprocesses (suchascell replication rates, age, diet, and
immune status) related to promotion ofcarcinogenesis is also
likely to be significant.
Asbiologicmarkersbecomemorepreciseandreproducible,
they canbeuseful inaccuratelycharacterizing thepopulation at
riskintermsofvariationinsensitivitytocarcinogenicexposures.
(Ofcourse, intraindividualvariabilityandassayvariability must
be well characterized and separated out from interindividual
variation.) Unfortunately, conventional representationofresults
ofbiomonitoring andmolecularepidemiologic studies interms
ofthe meanand standarddeviation andcoefficientofvariation
(aswehavebeenguiltyofinthispaper)doesnotaccuratelypor-
tray the extent of variability within a population. A useful
approachtoestimatingpopulationvariabilitybasedonsmalldata
setsisbasedonprobitanalysis, whichallowsexpressionofvalues
asmeasuresindependentofsamplesize. Forexample, usingthe
observedrangeofPAH-DNAvaluesfor35 foundry workers (11)
as an intermediate between the variation seen in two other oc-
cupational studies (40,41), onecanestimatethat95% ofastan-
dard population (±2 SD) would have 60-fold variability, and
99.7% (±3 SD) would have a 460-fold variation in adduct
formation.
Thefailureofcurrentprocedures forcarcinogenic riskassess-
ment to explicitly account forhuman interindividual variation
mayresultinasignificantunderstatementofcarcinogenicrisks
atlow doses, especially forthe most sensitive individuals, but
also forthepopulation as awhole (42).
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